Dear Quentin,  I have two sisters who have developed Alzheimer’s disease. My younger sister is actually more severely ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a new study.

Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was ...

Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Unfortunately, one in nine people in the United States who are 65 or older are diagnosed with Alzheimer’s, according to the ...

Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...

阿尔茨海默病（Alzheimer’s disease，AD） ...

Nov. 21—John Haldi had early-stage Alzheimer's disease when he began a local Aduhelm drug study in June 2020. For three years ...

Modeled after the state’s $6B cancer research fund, the dementia fund could pump hundreds of millions of dollars into Texas ...

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.